By: Ram May-Ron, Managing Partner

The life sciences industry is currently gripped by a collective “SBIR Panic.” Since the Small Business Innovation Research (SBIR) program lapsed last September, I have watched CEOs and CSOs freeze. They are staring at Washington, waiting for Senator Joni Ernst and the Senate Small Business Committee to resolve a stalemate over security provisions and “Section 402.”

My message to these executives is simple: Stop waiting for the SBIR. Start looking for the money.

In the movie Jerry Maguire, the famous line wasn’t “show me the specific legislative mechanism.” It was “Show me the money.” In the world of non-dilutive funding, we have become dangerously obsessed with the mechanism at the expense of the capital. The SBIR is a tool, a vehicle, a box to be checked. But it is not the only way—or even necessarily the best way—to fund your R&D in 2026.

The $1.27 Billion Giant Hiding in Plain Sight

While the industry laments the pause in SBIR solicitations, the “smart money” is already moving elsewhere. Look at the Congressionally Directed Medical Research Programs (CDMRP). In 2025, the budget for these DoD-managed programs sat at roughly $650 million. In the 2026 budget currently moving through the House, that figure has nearly doubled to $1.27 billion.

This is a massive, untapped pool of capital that doesn’t care about the SBIR lapse. If you are working on oncology, neurodegeneration, or infectious diseases, the CDMRP isn’t just a “backup plan”—it is a primary target with higher award ceilings and a clear mandate to fund innovation.

The NIH Shift: R01s are the New Industry Standard

Simultaneously, we are witnessing a strategic shift at the NIH. As topic-specific RFAs are scaled back, the agency is signaling a move toward “Parent” R01 and R21 mechanisms to fund industry-related R&D.

For years, many CEOs believed the R01 was “academic territory.” That is a myth we’ve been debunking at FreeMind for over two decades. The NIH is increasingly focused on pre-clinical, clinical, and translational research that has a clear path to the patient. Yes, the competition is greater, but as the clock ticks toward September 30, 2026, the NIH faces a “use it or lose it” mandate. By law, they must allocate their full 2026 budget—including the billions currently sitting in the “SBIR set-aside” that may be reprogrammed if the lapse continues.

The “FreeMind Way”: A Numbers Game

At FreeMind, we have been in the trenches for 26 years. We have seen government shutdowns, program lapses, and budget “cliffs.” Through all of it, our strategy has never changed because the math never changes.

Historically, the SBIR has only accounted for 33% to 45% of our total submissions. We have never treated the SBIR as our primary target. Why? Because a CEO’s job isn’t to be an expert in the Small Business Act; it’s to ensure their company is funded.

We have consistently won R01s, CDMRP awards, and BAA contracts for our clients by following one rule: Submit as many applications as possible to as many mechanisms as are available. If the SBIR door is locked, you don’t stop walking; you find the five other open windows.

The Bottom Line

We remain hopeful for a quick resolution to the SBIR lapse. It is a vital program that deserves a permanent home in the federal budget. But as a CEO, you cannot afford to let your clinical milestones be dictated by a Senate subcommittee’s schedule.

The funding is there. The budgets are growing. The September 30 deadline is looming. If you are waiting for an “SBIR” label to appear on a solicitation before you apply, you are failing your shareholders.

It’s time to stop talking about the mechanism. It’s time to show me the money.